Polyrizon (PLRZ) submitted a Pre-Request for Designation to the U.S. Food and Drug Administration for its PL-16 Viral Blocker, a non-pharmacological intranasal product designed to reduce exposure to airborne respiratory viruses, including influenza and cold viruses, by forming a temporary physical barrier on the nasal mucosa. The Pre-RFD submission initiates a formal regulatory dialogue with the FDA regarding the appropriate regulatory pathway for PL-16 Viral Blocker, based on its formulation and physical mode of action.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon Unveils Promising Results for Intranasal Naloxone Hydrogel
- Polyrizon’s naloxone hydrogel shows positive permeation kinetics
- Polyrizon Advances PL-14 Nasal Spray with FDA Meeting
- Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray
- Biotech Alert: Searches spiking for these stocks today